Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer

  • Kilickap, Saadettin (Department of Medical Oncology, Hacettepe University Institute of Cancer) ;
  • Kaya, Yalcin (Department of Medical Oncology, Cumhuriyet University Faculty of Medicine) ;
  • Yucel, Birsen (Department of Radiation Oncology, Cumhuriyet University Faculty of Medicine) ;
  • Tuncer, Ersin (Department of Pathology, Cumhuriyet University Faculty of Medicine) ;
  • Babacan, Nalan Akgul (Department of Medical Oncology, Cumhuriyet University Faculty of Medicine) ;
  • Elagoz, Sahande
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The prognostic value of the Ki67 expression level is yet unclear in breast cancer. The aim of this study was to investigate the association between Ki67 expression levels and prognostic factors such as grade, Her2 and hormone receptor expression status in breast cancers. Materials and Methods: Clinical and pathological features of the patients with breast cancer were retreived from the hospital records. Results: In this study, 163 patients with breast cancer were analyzed, with a mean age of $53.4{\pm}12.2$ years. Median Ki67 positivity was 20% and Ki67-high tumors were significantly associated with high grade (p<0.001), lymphovascular invasion (p=0.001), estrogen receptor (ER) negativity (p=0.035), Her2 positivity (p=0.001), advanced stage (p<0.001) and lymph node positivity (p<0.003). Lower Ki67 levels were significantly associated with longer median relapse-free and overall survival compared to those of higher Ki67 levels. Conclusions: High Ki67 expression is associated with ER negativity, Her2 positivity, higher grade and axillary lymph node involvement in breast cancers. The level of Ki67 expression is a prognostic factor predicting relapse-free and overall survival in breast cancer patients.

Keywords

References

  1. Beresford MJ, Wilson GD, Makris A (2006). Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res, 8, 216. https://doi.org/10.1186/bcr1618
  2. Bottini A, Berruti A, Bersiga A, et al (2001). Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer, 85, 1106-12. https://doi.org/10.1054/bjoc.2001.2048
  3. Colozza M, Azambuja E, Cardoso F, et al (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol, 16, 1723-39. https://doi.org/10.1093/annonc/mdi352
  4. de Azambuja E, Cardoso F, de Castro G Jr, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer, 96, 1504-13. https://doi.org/10.1038/sj.bjc.6603756
  5. DeCensi A, Guerrieri-Gonzaga A, Gandini S, et al (2011). Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol, 22, 582-7. https://doi.org/10.1093/annonc/mdq427
  6. Dowsett M, Smith IE, Ebbs SR, et al (2007). Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 99, 167-70. https://doi.org/10.1093/jnci/djk020
  7. Dowsett M, Smith IE, Ebbs SR, et al (2006). IMPACT Trialists Group. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res, 12, 1024-30 https://doi.org/10.1158/1078-0432.CCR-05-2127
  8. Ellis MJ, Tao Y, Luo J, et al (2008). Outcome prediction for estrogen receptorpositive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst, 100, 1380-8. https://doi.org/10.1093/jnci/djn309
  9. Fabian CJ, Kimler BF, Zalles CM, et al (2007). Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat, 106, 75-84. https://doi.org/10.1007/s10549-006-9476-5
  10. Faratian D, Munro A, Twelves C, Bartlett JMS (2009). Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology, 54, 254-7 https://doi.org/10.1111/j.1365-2559.2008.03191.x
  11. Gasparini G, Pozza F, Meli S, et al (1991). Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki67 and correlation with fl ow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res, 11, 2015-21.
  12. Gerdes J, Lemke H, Baisch H, et al (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 133, 1710-5.
  13. Gudlaugsson E, Klos J, Skaland I, et al (2013). Prognostic comparison of the proliferation markers mitotic activity index, phosphohistone H3, Ki67, steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T1-2N0M0 breast cancer. Pol J Pathol, 64, 1-8.
  14. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC Curves for Censored Survival Data and a Diagnostic Marker, Biometrics, 56, 337-44 https://doi.org/10.1111/j.0006-341X.2000.00337.x
  15. Heidebrecht HJ, Buck F, Haas K, Wacker HH, Parwaresch R (1996). Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki67'proteins. Cell Prolif, 29, 413-25. https://doi.org/10.1111/j.1365-2184.1996.tb00984.x
  16. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat,139, 539-52 https://doi.org/10.1007/s10549-013-2560-8
  17. Jalava P, Kuopio T, Juntti-Patinen L, et al (2006). Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassifi cation: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology, 48, 674-82. https://doi.org/10.1111/j.1365-2559.2006.02402.x
  18. Jemal A, Bray F, Center MM, et al (2011) Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  19. Jones RL, Salter J, A'Hern R, et al (2009). The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat, 116, 53-68. https://doi.org/10.1007/s10549-008-0081-7
  20. Klintman M, Bendahl PO, Grabau D, et al; South Sweden Breast Cancer Group (2010). The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol, 23, 251-9. https://doi.org/10.1038/modpathol.2009.167
  21. Sahin AA, Ro J, Ro JY, et al (1991). Ki67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer, 68, 549-57. https://doi.org/10.1002/1097-0142(19910801)68:3<549::AID-CNCR2820680318>3.0.CO;2-J
  22. Spyratos F, Ferrero-Pous M, Trassard M, et al (2002). Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer, 94, 2151-9 https://doi.org/10.1002/cncr.10458
  23. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008). Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast, 17, 323-34. https://doi.org/10.1016/j.breast.2008.02.002
  24. Talley LI, Grizzle WE, Waterbor JW, et al (2002). Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer, 98, 118-27 https://doi.org/10.1002/ijc.10171
  25. Tan PH, Bay BH, Yip G, et al (2005). Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol, 18, 374-81 https://doi.org/10.1038/modpathol.3800254
  26. Tanei T, Shimomura A, Shimazu K, et al (2011). Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol, 37, 155-61 https://doi.org/10.1016/j.ejso.2010.10.009
  27. Untch M, Gerber B, Mobus V, et al (2011). Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011). Breast Care, 6, 144-52. https://doi.org/10.1159/000327999
  28. Urruticoechea A, Smith IE, Dowsett M (2005). Proliferation marker Ki-67 in early breast cancer. J Clin Oncol, 23, 7212-20. https://doi.org/10.1200/JCO.2005.07.501
  29. van Diest PJ, van der WE, Baak JP (2004). Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol, 57, 675-81 https://doi.org/10.1136/jcp.2003.010777
  30. Viale G, Regan MM, Mastropasqua MG, et al; International Breast Cancer Study Group (2008). Predictive value of tumor Ki67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12 https://doi.org/10.1093/jnci/djm289
  31. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83 https://doi.org/10.1016/S1470-2045(09)70262-1

Cited by

  1. Breast Cancer in Tunisia: Association of Body Mass Index with Histopathological Aspects of Tumors vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6805
  2. Correlation between Ki67 and Histological Grade in Breast Cancer Patients Treated with Preoperative Chemotherapy vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10277
  3. Expression of Vimentin and Ki-67 Proteins in Cervical Squamous Cell Carcinoma and their Relationships with Clinicopathological Features vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4271
  4. Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4377
  5. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer vol.4, pp.1, 2015, https://doi.org/10.1186/s40064-015-0840-y
  6. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1243
  7. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1347
  8. Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients vol.12, pp.11, 2017, https://doi.org/10.1371/journal.pone.0188633
  9. Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017. vol.168, pp.2, 2018, https://doi.org/10.1007/s10549-017-4620-y